ArticleHepatology international2017
CSH guidelines for the diagnosis and treatment of drug-induced liver injury.
Registry-linked trialAbstract readEditorial
In one paragraph
Article in Hepatology international, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06618573 (Study on the Safety of Administering Isoniazid to Systemic Lupus Erythematosus Patients to Prevent Tuberculosis), which is not on this map. Cited by 144 papers, 4 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
144citing papers in PubMed, 4 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NCT06618573 phase2 / phase3recruitingnot on this mapstarted 2022, after this paper: background citation
Study on the Safety of Administering Isoniazid to Systemic Lupus Erythematosus Patients to Prevent Tuberculosis
Who cites it
144 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- The incidence of chronic drug-induced liver injury: a systematic review and meta-analysis.Frontiers in pharmacology · 2026Pooled it
- European guideline on obesity care in patients with gastrointestinal and liver diseases - Joint European Society for Clinical Nutrition and Metabolism / United European Gastroenterology guideline.United European gastroenterology journal · 2022Guideline
- Liver Injury in COVID-19 Patients with Drugs as Causatives: A Systematic Review of 996 DILI Cases Published 2020/2021 Based on RUCAM as Causality Assessment Method.International journal of molecular sciences · 2022Pooled it
- Comorbidities, Associated Diseases, and Risk Assessment in COVID-19-A Systematic Review.International journal of clinical practice · 2022Pooled it
- A Multicenter and Randomized Controlled Trial of Bicyclol in the Treatment of Statin-Induced Liver Injury.Medical science monitor : international medical journal of experimental and clinical research · 2017Trial
- Integrated biomarker analysis of multi-organ effects following MDMA and alcohol co-consumption in Pakistan: A pilot study.Toxicology reports · 2026Article
- Extract from Eucommia ulmoides Oliv. Leaves alleviates APAP-induced acute liver injury via reshaping gut microbiota and attenuating microbial bile acids metabolism disorder.Chinese medicine · 2026Article
- A serum Golgi Protein 73 (GP73)-based model for evaluating inflammation associated with drug-induced liver injury.Clinics (Sao Paulo, Brazil) · 2026Article
- Tripterygium Glycosides Extract-Induced Hepatic Cholestasis: A Mechanistic Study Using a Microfluidic Liver-on-a-Chip System.International journal of molecular sciences · 2026Article
- A Discovery in Compatibility of Traditional Chinese Medicine: Spatholobus suberectus Dunn Suppresses Tripterygium wilfordii Hook. f.-Induced Main Toxicity and Enhances Its Main Efficacy.Chemistry & biodiversity · 2026Article
- Olanzapine-Associated Hepatotoxicity in Bipolar Disorder: A Multicenter Real-World Study of Prevalence, Risk Factors, and Outcomes.Drug design, development and therapy · 2026Article
- Clinical profiles and risk predictors of drug-induced liver injury from pirfenidone and nintedanib used to treat idiopathic pulmonary fibrosis: a real-world analysis of a tertiary Chinese hospital cohort combined with FAERS data mining.Translational gastroenterology and hepatology · 2026Article
- SSRIs-induced liver injury adverse events: a data-based retrospective study and investigation of potential toxicological mechanisms.Frontiers in pharmacology · 2026Article
- Computed tomography manifestations of drug-induced liver injury according to type and severity of injury.Quantitative imaging in medicine and surgery · 2025Article
- Advances in mechanistic investigation and treatment of steroid-refractory ICI-induced liver injury.Clinical and experimental medicine · 2025Review
- [Expert opinions on the technical guiding principles for clinical trials of drugs in the treatment of chronic hepatitis B virus infection].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025Article
- Protective Effects of Ellagic Acid Against Arsenic-Induced Hepatotoxicity in Male Wistar Rats: Impact of Heme Oxygenase-1 Upregulation.Food science & nutrition · 2025Article
- Open questions on how metabolic dysfunction-associated steatotic liver disease shapes the course of drug-induced liver injury.World journal of hepatology · 2025Article
- Clinical features and prognosis of drug-induced liver injury in patients with non-alcoholic fatty liver.World journal of hepatology · 2025Article
- Drug-Induced Liver Injury-Pharmacological Spectrum Among Children.International journal of molecular sciences · 2025Review
84 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
39 authors.
Yue-Cheng YuLiver Disease Center of PLA, Bayi Hospital, Nanjing University of Chinese Medicine, Nanjing, 210002, China.ORCID http://orcid.org/0000-0003-3480-1829
Yi-Min MaoDepartment of Gastroenterology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200001, China. maoym11968@163.com.
Cheng-Wei ChenShanghai Liver Diseases Research Center, 85th Hospital, Nanjing Military Command, Shanghai, 200235, China. ccw2@163.com.
Jin-Jun ChenHepatology Unit, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
Jun ChenLiver Diseases Center, Second Xiangya Hospital, Central South University, Changsha, 410011, China.
Wen-Ming CongDepartment of Pathology, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, 201805, China.
Yang DingDepartment of Infectious Disease, Shengjing Hospital of China Medical University, Shenyang, 110004, China.
Zhong-Ping DuanArtificial Liver Center, Beijing Youan Hospital, Capital Medical University, Beijing, 100069, China.
Qing-Chun FuShanghai Liver Diseases Research Center, 85th Hospital, Nanjing Military Command, Shanghai, 200235, China.
Xiao-Yan GuoDepartment of Gastroenterology, Second Affiliated Hospital, Xi'an Jiaotong University, Xian, 710004, China.
Peng HuDepartment of Infectious Diseases, Institute for Viral Hepatitis, Second Affiliated Hospital, Chongqing Medical University, Chongqing, 400010, China.
Xi-Qi HuDepartment of Pathology, School of Medicine, Fudan University, Shanghai, 200433, China.
Ji-Dong JiaLiver Research Center, Beijing Friendship Hospital, Capital Medial University, Beijing, 100069, China.
Rong-Tao LaiDepartment of Infectious Diseases, Ruijin Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200025, China.
Dong-Liang LiDepartment of Hepatobiliary Disease, Fuzhou General Hospital of PLA, Fuzhou, 350025, China.
Ying-Xia LiuDepartment of Liver Disease, Shenzhen Third People's Hospital, Shenzhen, 518040, China.
Lun-Gen LuDepartment of Gastroenterology, Shanghai First People's Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200080, China.
Shi-Wu MaDepartment of Infectious Diseases, Kunming General Hospital of PLA, Kunming, 650032, China.
Xiong MaDepartment of Gastroenterology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200001, China.
Yue-Min NanDepartment of Traditional and Western Medical Hepatology, Third Affiliated Hospital, Hebei Medical University, Shijiazhuang, 050051, China.
Hong RenDepartment of Infectious Diseases, Institute for Viral Hepatitis, Second Affiliated Hospital, Chongqing Medical University, Chongqing, 400010, China.
Tao ShenDepartment of Microbiology and Infectious Disease Center, School of Basic Medical Sciences, Beijing University, Beijing, 100083, China.
Hao WangInstitute of Hepatology, People's Hospital, Beijing University, Beijing, 100044, China.
Ji-Yao WangDepartment of Gastroenterology, Zhongshan Hospital, School of Medicine, Fudan University, Shanghai, 200032, China.
Tai-Ling WangDepartment of Pathology, China-Japan Friendship Hospital, Capital Medical University, Beijing, 100029, China.
Xiao-Jin WangShanghai Liver Diseases Research Center, 85th Hospital, Nanjing Military Command, Shanghai, 200235, China.
Lai WeiInstitute of Hepatology, People's Hospital, Beijing University, Beijing, 100044, China.
Qing XieDepartment of Infectious Diseases, Ruijin Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200025, China.
Wen XieCenter of Liver Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100011, China.
Chang-Qing YangDepartment of Gastroenterology, Tongji Hospital, School of Medicine, Tongji University, Shanghai, 200065c, China.
Dong-Liang YangDepartment of Infectious Disease, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Yan-Yan YuDepartment of Infectious Disease, Beijing University First Hospital, Beijing, 100034, China.
Min-de ZengDepartment of Gastroenterology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200001, China.
Li ZhangDongfang Hospital, Beijing University of Chinese Medicine, Beijing, 100078c, China.
Xin-Yan ZhaoLiver Research Center, Beijing Friendship Hospital, Capital Medial University, Beijing, 100069, China.
Hui ZhuangDepartment of Microbiology and Infectious Disease Center, School of Basic Medical Sciences, Beijing University, Beijing, 100083, China.
Drug-induced Liver Injury (DILI) Study Group
Chinese Society of Hepatology (CSH)
Chinese Medical Association (CMA)
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug-induced liver injury (DILI) is an important clinical problem, which has received more attention in recent decades. It can be induced by small chemical molecules, biological agents, traditional Chinese medicines (TCM), natural medicines (NM), health products (HP), and dietary supplements (DS). Idiosyncratic DILI is far more common than intrinsic DILI clinically and can be classified into hepatocellular injury, cholestatic injury, hepatocellular-cholestatic mixed injury, and vascular injury based on the types of injured target cells. The CSH guidelines summarized the epidemiology, pathogenesis, pathology, and clinical manifestation and gives 16 evidence-based recommendations on diagnosis, differential diagnosis, treatment, and prevention of DILI.
Indexed as
Anti-Bacterial AgentsAnti-Infective AgentsChemical and Drug Induced Liver InjuryChinaCholestasisDiagnosis, DifferentialDietary SupplementsDrugs, Chinese HerbalFemaleGuidelines as TopicHumansIncidenceLiver DiseasesMalePrognosisRisk FactorsAnti-Bacterial AgentsAnti-Infective AgentsDrugs, Chinese HerbalClinical typeDiagnosisDifferential diagnosisDrug-induced liver injuryEpidemiologyPathogenesisPathologyPreventionRecommendationsTreatment
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT06618573ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.